Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
589-601
Author(s):
S. Tacconelli, M. L.. Capone and P. Patrignani
Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
669-677
Author(s):
K. Tanaka and N. Ogawa
Refining Genetic Approaches for Identifying Behavioral Loci
Journal:
Current Genomics
Volume:
5
Page:
169-174
Author(s):
Robert A Philibert, Remi J Cadoret and Howard K Gershenfeld
Preface
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
i-i
Author(s):
Peter W. Radke
Update on Sirolimus Drug-Eluting Stents
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
337-348
Author(s):
Nicholas Kipshidze, Martin B. Leon, Mykola Tsapenko, Robert Falotico, Gregory A. Kopia and Jeffrey Moses
Dexamethasone and Restenosis After Coronary Stent Implantation: New Indication for an Old Drug?
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
349-355
Author(s):
Peter W. Radke, Christian Weber, Axel Kaiser, Andreas Schober and Rainer Hoffmann
Low-Molecular Weight Heparins in Percutaneous Coronary Interventions: Current Concepts, Problems, and Perspectives
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
375-386
Author(s):
Graf J. and Janssens U.
GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
387-398
Author(s):
Dery J.P., Harrington R.A. and Tcheng J.E.
Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
425-432
Author(s):
Claudio Napoli and Vincenzo Sica
Death Receptors as Targets of Cancer Therapeutics
Journal:
Current Cancer Drug Targets
Volume:
4
Page:
97-104
Author(s):
M. Saeed Sheikh and Ying Huang